Text Size

Review of clinical outcomes of a cationic emulsion tear substitute in patients with dry eye disease

Labetoulle M, Garhöfer G, Ismail D, Garrigue JS, Amrane M, Guillon M, Aragona P, Baudouin C.


  • 2024
  • Acta Ophthalmologica
View publication
  • Therapeutic Area

    Front of the eye (FOTE)

  • Categories

    Clinical development

  • Affiliations

    Ophthalmology, South Paris University Hospital-APHP, Le Kremlin-Bicêtre, France; IDMIT Infrastructure, Inserm, Cedex, France; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; Santen SAS, Evry, France; Ocular Technology Group - International, London, UK; Eye Clinic, Department of Biomedical Sciences, University of Messina, Messina, Italy; Department of Ophthalmology, Quinze-Vingts Hospital, IHU FOReSIGHT, Paris, France; University Paris Saclay, Versailles Saint-Quentin en Yvelines, Paris, France.

Related Publications

Epinastine Cream: A Novel Once-Daily Therapeutic Agent for Allergic Conjunctivitis

Ogura N., Fujisawa K., Kato M.


NOVATIVE: A Phase II/III, Multicenter, Double-masked, Randomized Study of Cyclosporine A 0.05% and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients with Vernal Keratoconjunctivitis

Leonardi A.; Pisella P.-J.; Benítez-del-Castillo J.M.; Amrane M.; Ismail D.; Doan S.; Bremond-Gignac D.


Efficacy and Tolerance of Nova22007 Versus Vehicle in Patients With Vernal Keratoconjunctivitis (NOVATIVE): A Phase II/III, Multicenter, Double-masked, Randomized Study of 0.05% Cyclosporine A and 0.1% Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Vernal Keratoconjunctivitis

Leonardi A, Pisella PJ, Benítez-Del-Castillo JM, Amrane M, Ismail D, Doan S, Bremond-Gignac D.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022